Clinical Trial

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Study acronym: PALM-ILD
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.
Protocol Amendment History 5 changes
notable Trial sites expanded: 109 -> 145 locations 2026-08-15
notable Trial sites expanded: 96 -> 109 locations 2026-05-28
notable Trial sites expanded: 68 -> 96 locations 2026-05-05
notable Trial sites expanded: 49 -> 68 locations 2026-04-15
notable Trial sites expanded: 30 -> 49 locations 2026-03-31
Trial Details
NCT Number NCT07179380
Lead Sponsor Insmed Incorporated
Conditions Pulmonary Hypertension, Interstitial Lung Disease
Enrollment 344 participants
Start Date 2026-01-07
Primary Completion 2028-12-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-14